FDG PET/CT:EANM procedure guidelines for tumour imaging: version 2.0 by Boellaard, Ronald et al.
 
 
 University of Groningen
FDG PET/CT
Boellaard, Ronald; Delgado-Bolton, Roberto; Oyen, Wim J. G.; Giammarile, Francesco;
Tatsch, Klaus; Eschner, Wolfgang; Verzijlbergen, Fred J.; Barrington, Sally F.; Pike, Lucy C.;
Weber, Wolfgang A.
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
DOI:
10.1007/s00259-014-2961-x
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen,
F. J., Barrington, S. F., Pike, L. C., Weber, W. A., Stroobants, S., Delbeke, D., Donohoe, K. J., Holbrook,
S., Graham, M. M., Testanera, G., Hoekstra, O. S., Zijlstra, J., Visser, E., ... Krause, B. J. (2015). FDG
PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear
Medicine and Molecular Imaging, 42(2), 328-354. https://doi.org/10.1007/s00259-014-2961-x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
GUIDELINES
FDG PET/CT: EANM procedure guidelines for tumour imaging:
version 2.0
Ronald Boellaard & Roberto Delgado-Bolton & Wim J. G. Oyen & Francesco Giammarile &
Klaus Tatsch & Wolfgang Eschner & Fred J. Verzijlbergen & Sally F. Barrington &
Lucy C. Pike & Wolfgang A. Weber & Sigrid Stroobants & Dominique Delbeke & Kevin J.
Donohoe & Scott Holbrook & Michael M. Graham & Giorgio Testanera & Otto S. Hoekstra &
Josee Zijlstra & Eric Visser & Corneline J. Hoekstra & Jan Pruim & Antoon Willemsen &
Bertjan Arends & Jörg Kotzerke & Andreas Bockisch & Thomas Beyer & Arturo Chiti &
Bernd J. Krause
Received: 10 November 2014 /Accepted: 12 November 2014 /Published online: 2 December 2014
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract The purpose of these guidelines is to assist
physicians in recommending, performing, interpreting
and reporting the results of FDG PET/CT for oncolog-
ical imaging of adult patients. PET is a quantitative
imaging technique and therefore requires a common
quality control (QC)/quality assurance (QA) procedure
to maintain the accuracy and precision of quantitation.
Repeatability and reproducibility are two essential re-
quirements for any quantitative measurement and/or im-
aging biomarker. Repeatability relates to the uncertainty
in obtaining the same result in the same patient when
he or she is examined more than once on the same
R. Boellaard (*) :O. S. Hoekstra
Department of Radiology & Nuclear Medicine, VU University




Department of Diagnostic Imaging (Radiology) and Nuclear
Medicine, San Pedro Hospital and Centre for Biomedical Research of
La Rioja (CIBIR), University of La Rioja, Logroño, La Rioja, Spain
W. J. G. Oyen : E. Visser
Department of Radiology & Nuclear Medicine, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands
F. Giammarile
Department of NuclearMedicine, Centre Hospitalier Universitaire de
Lyon, Lyon, France
K. Tatsch
Department of Nuclear Medicine, Municipal Hospital Karlsruhe Inc.,
Karlsruhe, Germany
W. Eschner
Department of Nuclear Medicine, University of Cologne, Cologne,
Germany
F. J. Verzijlbergen
Department of Nuclear Medicine, Erasmus Medical Center,
Rotterdam, The Netherlands
S. F. Barrington : L. C. Pike
PET Imaging Centre, St Thomas’ Hospital, Division of Imaging
Sciences and Biomedical Engineering, King’s College London,
King’s Health Partners, London, UK
W. A. Weber
Department of Radiology, Memorial Sloan Kettering Center, New
York, NY, USA
S. Stroobants
Department of Nuclear Medicine, Antwerp University Hospital,
Antwerp, Belgium
D. Delbeke
Department of Radiology and Radiological Sciences, Vanderbilt
University Medical Center, Nashville, TN, USA
K. J. Donohoe
Beth Israel Deaconess Medical Center, Boston, MA, USA
S. Holbrook
Invivo Molecular Imaging LLC, Gray, TN, USA
M. M. Graham
Department of Radiology, University of Iowa, Iowa City, IA, USA
G. Testanera :A. Chiti
Department of Nuclear Medicine, Humanitas Clinical and Research
Center, Rozzano, MI, Italy
Eur J Nucl Med Mol Imaging (2015) 42:328–354
DOI 10.1007/s00259-014-2961-x
system. However, imaging biomarkers should also have
adequate reproducibility, i.e. the ability to yield the
same result in the same patient when that patient is
examined on different systems and at different imaging
sites. Adequate repeatability and reproducibility are es-
sential for the clinical management of patients and the
use of FDG PET/CT within multicentre trials. A com-
mon standardised imaging procedure will help promote
the appropriate use of FDG PET/CT imaging and in-
crease the value of publications and, therefore, their
contribution to evidence-based medicine. Moreover, con-
sistency in numerical values between platforms and
institutes that acquire the data will potentially enhance
the role of semiquantitative and quantitative image in-
terpretation. Precision and accuracy are additionally im-
portant as FDG PET/CT is used to evaluate tumour
response as well as for diagnosis, prognosis and staging.
Therefore both the previous and these new guidelines
specifically aim to achieve standardised uptake value
harmonisation in multicentre settings.
Keywords FDG . PET/CT . Imaging procedure . Tumour .
Oncology . Quantification
Preamble
The European Association of Nuclear Medicine (EANM) is a
professional nonprofit medical association that facilitates com-
munication worldwide among individuals pursuing clinical and
research excellence in nuclear medicine. The EANM was
founded in 1985.
These guidelines are intended to assist practitioners in
providing appropriate nuclear medicine care for patients. They
are not inflexible rules or requirements of practice and are not
intended, nor should they be used, to establish a legal standard
of care.
The ultimate judgment regarding the propriety of any specific
procedure or course of action must be made by medical profes-
sionals taking into account the unique circumstances of each
case. Thus, there is no implication that an approach differing
from the guidelines, standing alone, is below the standard of care.
To the contrary, a conscientious practitioner may responsibly
adopt a course of action different from that set out in the guide-
lines when, in the reasonable judgment of the practitioner, such
course of action is indicated by the condition of the patient,
limitations of available resources or advances in knowledge or
technology subsequent to publication of the guidelines.
The practice of medicine involves not only the science but
also the art of dealing with the prevention, diagnosis, alleviation
and treatment of disease. The variety and complexity of human
conditions make it impossible to always reach the most appro-
priate diagnosis or to predict with certainty a particular response
to treatment. Therefore, it should be recognised that adherence
to these guidelines will not ensure an accurate diagnosis or a
successful outcome. All that should be expected is that the
practitioner will follow a reasonable course of action based on
current knowledge, available resources and the needs of the
patient to deliver effective and safe medical care. The sole
purpose of these guidelines is to assist practitioners in achieving
this objective.
Introduction
18F-FDG (FDG) PET imaging is a noninvasive diagnostic tool
that provides tomographic images and can be used to obtain
quantitative parameters concerning the metabolic activity of
target tissues. 18F is a cyclotron-produced radioisotope of fluorine
that emits positrons and has a short half-life (109.7min). It allows
labelling of numerous molecular tracers that can be imaged
within a few hours (typically <3 h) after injection. FDG is an
analogue of glucose and is taken up by living cells via cell
membrane glucose transporters and subsequently incorporated
into the first step of the normal glycolytic pathway.
PET is a tomographic technique that measures the three-
dimensional distribution of positron-emitting labelled radio-
tracers. PET allows noninvasive quantitative assessment of
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biochemical and functional processes. The most commonly
used tracer at present is the 18F-labelled glucose analogue
FDG. FDG accumulation in tissue is proportional to the
amount of glucose utilisation. Increased consumption of glu-
cose is characteristic of most cancers and is in part related to
overexpression of the GLUT glucose transporters and in-
creased hexokinase activity. FDG PET has been proven to
be a sensitive imaging modality for detection, staging and
restaging and therapy response assessment in oncology
[1–13]. FDG PET/CT provides essential information for radi-
ation treatment planning, helping with critical decisions when
delineating tumour volumes [14, 15].
CT uses a combined X-ray transmission source and detec-
tor system rotating around the subject to generate tomographic
images. CT allows not only attenuation correction but also the
visualisation of morphological and anatomical structures with
a high spatial resolution. Anatomical and morphological in-
formation derived from CT can be used to improve the
localisation, extent and characterisation of lesions detected
by FDG PET. These guidelines focus on the use of FDG
PET/CT in oncology, where PET/CT continues to gain impor-
tance. Recently, combined or integrated PET and MRI sys-
tems (PET/MRI) have come onto the market. PET/MRI tech-
nology is, however, still in development and is not yet widely
available [16, 17]. Therefore, this version of the guidelines
does not address FDG PET/MRI, although currently the quan-
titative performance of FDG PET/MRI is being explored as a
scientific project within EANM Research Limited (EARL).
Goals
The purpose of these guidelines is to assist physicians in
recommending, performing, interpreting and reporting the results
of FDG PET/CT for oncological imaging of adult and paediatric
patients. PET is a quantitative imaging technique and therefore
requires a common quality control (QC)/quality assurance (QA)
procedure to maintain the accuracy and precision of quantitation
[18]. Repeatability and reproducibility are two essential require-
ments for any quantitative measurement and/or imaging biomark-
er. Repeatability relates to the uncertainty in obtaining the same
result in the same patient when he or she is examined more than
once on the same system. However, imaging biomarkers should
also have adequate reproducibility, i.e. the ability to yield the same
result in the same patient when that patient is examined on
different systems and at different imaging sites. Adequate repeat-
ability and reproducibility are essential for the clinical manage-
ment of patients and the use of FDG PET/CTwithin multicentre
trials. A common standardised imaging procedure will help pro-
mote the appropriate use of FDG PET/CT imaging and increase
the value of publications and, therefore, their contribution to
evidence-based medicine. Moreover, consistency in numerical
values between platforms and institutes that acquire the data will
potentially enhance the role of semi-quantitative and quantitative
image interpretation. Precision and accuracy are additionally im-
portant as FDG PET/CT is used to evaluate tumour response as
well as for diagnosis, prognosis and staging. Therefore both the
previous and these new guidelines specifically aim to achieve
standardised uptake value (SUV) harmonisation in multicentre
settings.
These guidelines address general information about FDG
PET/CT and are provided to help the physician, physicist and
technologist perform, interpret and document quantitative
FDG PET/CT examinat ions, but concentrate on
harmonisation/standardisation of diagnostic quality and quan-
titative information in oncology imaging of adult patients.
These guidelines present a standardised imaging procedure
for static FDG PET/CT data acquisition, QC and QA. Quan-
tification of FDG PET/CT is defined as quantification using
SUVs [19] because the SUV represents the most commonly
used semiquantitative parameter for analysis of tracer uptake.
Furthermore, this new version of the guidelines only addresses
combined or integrated whole-body 3D PET/CT systems.
These guidelines build upon the earlier published European
procedure guidelines for quantitative FDG PET and PET/CT
for tumour imaging [20] and the SNMMI procedure guide-
lines for tumour imaging with 18F-FDG PET/CT 1.0 [21]. For
a detailed history of the document, refer to section History of
the document. For FDG PET/CTstudies in paediatric patients,
refer to the specific guidelines [22].
Definitions
& An integrated or multimodality PET/CT system is a com-
bination of a PET and a CT system with a single, con-
joined patient handling system (table).
& PET/CT allows sequential acquisition of PET and CT
portions of the examination with the patient in the same
position for both examinations. Both datasets are intrinsi-
cally coregistered.
& An FDG PET/CT examination may cover various coaxial
imaging ranges; these ranges are described as follows,
with different denominations depending on European
standard (GL 1.0) or US standard (defined in Current
Procedural Terminology 2005):
– Whole-body imaging: From the top of the head through
the feet (standard for both Europe and the US).
– Torso imaging: Base of the skull to mid-thigh. Covers
most of the relevant portions of the body in many onco-
logical diseases (standard for both Europe and the US). If
indicated, cranially extended torso imaging may also
cover the brain in the same scan (from the top of the head
to mid-thigh).
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– Limited-area tumour imaging: For the evaluation of
tumour-related changes in a limited portion of the body.
– Whole-body or torso imaging combined with dedicated
brain imaging: Dedicated brain imaging combined with
whole-body or torso imaging from base of skull.
& In PET/CT studies attenuation correction and scatter
correction are performed using the CT transmission
data.
& A PET/CT examination can include different types
of CT scan depending on the CT characteristics, the
dose and the use (or not) of oral and/or intravenous
contrast agents:
– Low-dose CT scan: CT scan that is performed only for
attenuation correction (CT-AC) and anatomical correla-
tion of PET findings (with reduced voltage and/or current
of the X-ray tube settings), i.e. a low-dose CT is not
intended a priori for a dedicated radiological
interpretation.
– Diagnostic CTscan: CT scan with or without intravenous
and/or oral contrast agents, commonly using higher X-ray
doses than low-dose scans. Diagnostic CT scan should be
performed according to applicable local or national pro-
tocols and guidelines.
Common clinical indications
FDG PET/CT is a rapidly evolving imaging modality at both
the national and the international levels, with some striking
differences between individual countries. FDG PET/CT has
become one of the cornerstones of patient management in
oncology.
Indications for FDG PET/CT include [10–12, 20, 21], but
are not limited to, the following:
& Differentiation of benign from malignant lesions
& Searching for an unknown primary tumour whenmetastatic
disease is discovered as the first manifestation of cancer or
when the patient presents with a paraneoplastic syndrome.
& Staging patients with known malignancies.
& Monitoring the effect of therapy on known malignancies.
& Determining whether residual abnormalities detected on
physical examination or on other imaging studies follow-
ing treatment represent tumour or posttreatment fibrosis or
necrosis.
& Detecting tumour recurrence, especially in the presence of
elevated tumour markers.
& Selection of the region of tumour most likely to yield
diagnostic information for biopsy.
& Guiding radiation therapy planning.
Other documents include further indications for FDG PET/
CT [10, 20]. The clinical utility of this valuable technology
continues to expand in oncology and therefore an exhaustive
list of appropriate indications would not be possible or remain
final for long.
FDG PET/CT also has an increasingly relevant role in
inflammation and infection imaging [23], cardiology and neu-
rology. In these areas the FDG PET/CT procedure may require
specific elements not addressed in these guidelines.
Regulatory issues
There is consistent progress in the field, with regular new
literature and registration of FDG for several indications by
the European Medicines Agency. In the United States, FDG is
approved by the Food and Drug Administration for all onco-
logical indications.
Qualifications and responsibilities of personnel
In Europe, the certified nuclear medicine physician who per-
formed the study and signed the report is responsible for the
procedure, according to national laws and rules. In the United
States, see the SNMMI Guideline for General Imaging [24].
Procedure/specification of the examination
Request
The request for the examination should include sufficient
medical information to demonstrate medical necessity and
should at least include the diagnosis and questions to be
answered.
Review of the medical history
The medical record should be reviewed with a special focus
on the diagnosis (type of cancer and known sites), oncological
history and relevant comorbidity (especially infection/
inflammation and diabetes mellitus). A short interview with
the patient and/or family can help clarify some of these issues.
Relevant laboratory tests should be considered. The results of
prior imaging studies should be available to review, including
planar radiography, CT, MRI, bone scanning and FDG PET/
CT. Relevant prior studies should be directly compared with
current imaging findings when possible. The following list
shows all aspects that should be considered in the review:
& Tumour type (if known) and known tumour sites.
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& Oncological history and relevant comorbidity (especially
infection/inflammation and diabetes mellitus).
& Neurological or psychiatric clinical presentations, in-
cluding suspected neurological paraneoplastic
syndromes.
& Height and body weight (these must be determined pre-
cisely in the case of SUV measurements, see below).
Weight must be measured directly prior to each FDG
PET/CT examination (also in the case of longitudinal
studies) because body weight often changes during the
course of disease.
& Serum glucose, date, time.
& Full overview of current and recently used medication,
especially (but not limited to) antidiabetic medication,
corticosteroids, growth factors and sedatives. In the case
of therapy evaluation: type and date of last therapeutic
intervention.
& Results of other imaging tests (especially CT, MRI and
previous PET/CT), including dates of acquisition, full
reports and, if possible, DICOM data of the referred
studies for comparison.
& Other examinations performed earlier on the same day
as the PET/CT is scheduled. If intravenous contrast
agent has been used or specific preparation followed
in the 24 – 48 h prior to the FDG PET/CT examination,
the situation should be evaluated and noted; if possible
such circumstances should be avoided in patient
scheduling.
& Allergy to contrast agents. If an FDG PET/CT examina-
tion with intravenous CT contrast agent is strictly neces-
sary the referring physician must indicate the
premedication protocol to prepare the patient.
& Renal function. Creatinine and/or glomerular filtration
should be evaluated, according to national guidelines, if
intravenous contrast agent is to be used. If renal function is
suboptimal and an FDG PET/CT examination with intra-
venous CT contrast agent is necessary, then the referring
physician can initiate the protocol for prevention of neph-
rotoxicity (hydrate the patient and repeat the blood test,
and if necessary prescribe medication for prevention of
nephrotoxicity).
Patient preparation and precautions
The main purpose of patient preparation to reduce tracer
uptake in normal tissue (kidneys, bladder, skeletal muscle,
myocardium, brown fat) while maintaining and optimising
tracer uptake in the target structures (tumour tissue) and keep-
ing patient radiation exposure levels as low as reasonably
possible (ALARA). A generally applicable protocol is
outlined below.
Pregnancy (suspected or confirmed)
For any diagnostic procedure in a female patient known or
suspected to be pregnant, a clinical decision is necessary in
which the benefits are weighed against the possible harm. The
International Commission on Radiological Protection (ICRP)
reports that for an adult patient the administration of 259MBq
(7 mCi) of FDG results in an absorbed radiation dose of
4.7 mGy to the nongravid uterus (i.e. 1.8×10−2 mGy/MBq)
[25]. Direct measurements of FDG uptake in a case study
suggested somewhat higher doses than are currently provided
in standard models [26]. A pregnancy test may help with the
decision, provided the 10 day postovulation blackout is un-
derstood. In the event of doubt and in the absence of an
emergency, the 10 day rule should be adopted. In Europe,
national guidelines may apply.
Breastfeeding
The ICRP does not recommend interruption of breastfeeding
after FDG administration since little FDG is excreted in the
milk [25]. However, as the lactating breast accumulates FDG
[27], it is suggested that contact between mother and child be
limited for 12 h after injection of FDG to reduce the radiation
dose that the infant receives from external exposure to radia-
tion emitted by the mother. It is recommended that the infant
be breastfed just before injection, to maximise the time be-
tween the injection and the next feed. Breast milk may be
expressed and fed to the infant via a bottle for 12 h to help
minimise the interruption in close, prolonged contact between
the infant and the mother.
Instructions to patients
Nondiabetic patients should not consume any food, simple
carbohydrates or liquids other than plain (unflavoured) water
for at least 4 h prior to the start of the FDG PET/CT study (i.e.
with respect to the time of injection of FDG). In practice, this
means that patients scheduled to undergo the FDG PET/CT
study in the morning should not eat after midnight and pref-
erably should have only a light meal (no alcohol and only a
small amount of carbohydrates) during the evening prior to the
FDG PET/CT study. Those scheduled for an afternoon FDG
PET/CT study may have a light breakfast at least 4 h prior to
the time of their PET/CT examination appointment. Medica-
tion can be taken as prescribed.
& Adequate prehydration is important to ensure a sufficiently
low concentration of FDG in the urine (fewer artefacts) and
for radiation safety reasons. For example, consumption of
1 L of water during the 2 h prior to injection is suggested.
Where necessary, account for the volume of water in oral
contrast agent if it is to be given for a diagnostic CT scan.
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& Coffee or caffeinated beverages are not recommended
because even if “sugarless” they may contain traces of
simple carbohydrates and have the potential to induce
excitant effects; this may also be the case for “sugar-free”
beverages.
& Parenteral nutrition and intravenous fluids containing glu-
cose should be discontinued at least 4 h before the time of
FDG injection. In addition, the infusion used to administer
intravenous prehydration must not contain glucose.
& During the injection of FDG and the subsequent uptake
phase, the patient should remain seated or recumbent and
silent (this is particularly true for head and neck cancer
patients) to minimise FDG uptake in muscles. The patient
should be kept warm starting 30 – 60 min before the
injection of FDG and continuing throughout the subse-
quent uptake period and examination to minimise FDG
accumulation in brown fat (especially relevant in winter or
if the room is air-conditioned).
& Patients must avoid strenuous exercise for at least 6 h
before the FDG PET/CT study, and preferably for 24 h.
& Patients should void immediately prior to the PET/CT
examination to reduce bladder activity.
& The patient should be able to lie still in the PET/CTsystem
for the duration of the examination (20 – 45 min). A
specific inquiry about claustrophobia at the time the pa-
tient is scheduled for the study may decrease the number
of nondiagnostic studies and cancellations, and allow
premedication planning.
& If possible, the patient should put his/her arms above the
head; proper support devices (e.g. foam pallets) provided
by the manufacturers should be employed whenever
feasible.
& When a diagnostic contrast-enhanced CT examination
with intravenous contrast agent is to be performed, spe-
cific indications must be followed (see later in these
guidelines).
Serum glucose level before FDG administration
The main objectives of patient preparation with at least 4 h of
fasting are to ensure low blood glucose and low insulinaemia,
as insulin is directly responsible for glucose uptake by
nontumour cells [28]. Although efforts should be made to
decrease blood glucose to normal levels (typically
4 – 7 mmol/L) and insulinaemia to low levels, if the study is
indicated in a patient with unstable (“brittle”) or poorly con-
trolled diabetes (often associated with infection),
hyperglycaemia should not represent an absolute contraindi-
cation to the study, as fasting hyperglycaemia does not hamper
the clinical value of FDG PET [28]. Therefore we recommend
the same advice and suggest recording the blood glucose level
and any other information that could be relevant for interpre-
tation of the examination.
Blood glucose level must be measured prior to administer-
ing FDG. A glucose meter (or glucometer) or a similar bedside
device capable of performing overall blood glucose measure-
ments can be used for this purpose, but a blood glucose test
must be performed with a calibrated and validated method if
plasma glucose level is to be used for correction of SUV
measurements [29].
It is good practice to check the blood glucose of the patient
on arrival at the imaging centre to ensure the level is not too
low (not below 4 mmol/L, about 70 mg/dL) or too high, since
this may avoid an unnecessary wait. For diabetic patients, it is
suggested that blood glucose level is checked upon arrival in
order to initiate, if necessary, manoeuvres to lower the blood
glucose level as soon as possible. Certain patients can be
asked to arrive at the imaging centre earlier than usual to allow
more time to correct possible hyperglycaemic situations.
For clinical studies:
& If the plasma glucose level is lower than 11mmol/L (about
200 mg/dL), the FDG PET/CT study can be performed.
& If the plasma glucose level is higher than or equal to
11 mmol/L (about 200 mg/dL), the FDG PET/CT study
should be rescheduled or the patient excluded depending on
the patient’s circumstances and the trial being conducted.
For research studies:
& The recommended upper plasma glucose levels may range
between 7 and 8.3 mmol/L (126 mg/dL and 150 mg/dL)
[30]; the upper threshold should be specified in the study
protocol. Patients who fall outside the specified range of
serum glucose levels are often excluded from the study,
but reference should be made to the specific study proto-
col in reaching this decision.
It should be stated whether the SUV reported is corrected for
glucose and, if so, values should be given with and without
glucose correction. Glucose levels should be recorded and re-
ported, to allow the calculation of glucose corrected SUV post
hoc. SUVmay be reported with glucose correction although this
is not common practice in many clinical centres. Note that
specifically in response assessment studies, blood glucose levels
may change with therapy, and it is strongly recommended that
blood glucose levels be measured using validated and calibrated
methods (no bedside devices) during sequential FDG PET/CT
studies. There are few studies in the literature using glucose
normalised SUVs and there is no clear evidence that glucose
normalisation improves response monitoring or prediction of
outcome as compared to uncorrected SUVs. It is also unclear
whether the concept of glucose normalisation is valid for
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malignant tumours. Glucose normalisation implies that glucose
metabolic rates are tightly regulated. In some malignancies with
unregulated glucose metabolic rates, uncorrected SUVs can be
more stable than glucose corrected SUVs [31].
Reduction of the blood glucose level by administration of
insulin can be considered, but the FDG PET/CT study should
also be postponed depending on the type and route of the
administration of insulin. Insulin should not be given to re-
duce glucose levels (this leads to greater muscle uptake of
FDG) unless the interval between administration of insulin
and administration of FDG is more than 4 h. The preferred
route of administration is a subcutaneous injection. If insulin
is administered it should be rapid-acting insulin (which
reaches the bloodstream 15 min after injection, peaks at
60 min and is effective for 2 – 4 h). Other insulin types that
are not recommended for immediate or delayed FDG PET/CT
imaging are: regular or short-acting insulin (which reaches the
bloodstream 30 min after injection, peaks at 2 – 3 h and is
effective for 3 – 6 h), intermediate-acting insulin (effective for
12 – 18 h) or long-acting insulin (effective for 24 h). It is also
possible to lower blood glucose in patients just above the cut-
off threshold by asking them to hydrate while ambulating and
recheck the blood glucose periodically until an acceptable
level has been achieved. Recently, intravenous administration
of insulin before FDG administration has been discussed, but
it has not yet been validated [32].
Diabetes
The following recommendations apply to patients with diabe-
tes mellitus:
Type II diabetes mellitus (controlled by oral medication)
& The FDG PET/CT study should preferably be performed
in the late morning.
& Patients must comply with the fasting rules indicated
above.
& Patients continue to take oral medication to control their
blood sugar. If intravenous contrast agent is going to be
administered, metformin should be discontinued at the
time of the procedure and withheld for 48 h after the
procedure (see below).
Type I diabetes mellitus and insulin-dependent type II diabetes
mellitus
& Ideally, an attempt should be made to achieve nor-
mal glycaemic values prior to the FDG PET/CT
study, in consultation with the patient and his/her
attending medical doctor.
& There are three options for scheduling the FDG PET/CT
study:
1. It can be scheduled for late morning or midday. The
patient should eat a normal breakfast by early morn-
ing (around 7.00 a.m.) and inject the normal amount
of insulin. Thereafter the patient should not consume
any more food or fluids, apart from the prescribed
amount of water. FDG should be injected no sooner
than 4 h after subcutaneous injection of rapid-acting
insulin or 6 h after subcutaneous injection of short-
acting insulin. FDG administration is not recom-
mended on the same day after injection of
intermediate-acting and/or long-acting insulin.
2. It can be scheduled for early morning. The presence
of intermediate-acting insulin administered the eve-
ning before should not interfere with the PET/CT
study and glycaemia will probably still be under
control. If long-acting insulin has been used the eve-
ning before, there could be a slight interference with
the PET/CT study. Thus, if this is the preferred sched-
ule, intermediate-acting (instead of long-acting) insu-
lin is recommended. The patient should eat a normal
breakfast after the PET/CT study and inject the nor-
mal amount of insulin.
3. In patients on continuous insulin infusion, if possible
the FDG PET/CT study should be scheduled for early
in the morning. The insulin pump should be switched
off for at least 4 h prior to FDG administration. The
patient can have breakfast after the FDG PET/CT
study and switch on continuous insulin infusion.
Kidney failure
FDG imaging can be performed in patients with kidney fail-
ure, although the image quality may be suboptimal and prone
to interpretation pitfalls [33].
Recommendations for image optimisation in specific
circumstances, and extra notes
& There is no reason for routine administration of sedatives
(e.g. short-acting benzodiazepines) in adult patients. Seda-
tives may be considered in the case of tumours in the head
and neck region to reduce muscle uptake or in claustro-
phobic patients. A number of agents have been tried and
are being tested to reduce brown fat uptake (e.g. 5 mg of
intravenous diazepam, administered 10 min prior to FDG
[34], or 80 mg of propranolol given orally 2 h before FDG
administration [35]), but conflicting results have been re-
ported [36]. Patients should be instructed not to drive a car
and to travel home accompanied after sedation.
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& When the patient is referred for the evaluation of a lesion
in the heart or very close to the myocardium, additional
dietary recommendations can be helpful. While there are
many options for decreasing normal glucose uptake by the
myocardium, common recommendations may include in-
structions for the patient to follow a low carbohydrate diet
for 24 h prior to the PET/CT study, or at least a low
carbohydrate meal before starting the 6 h period of fasting
before the study [37, 38]. The low carbohydrate diet helps
switch the myocardium from using glucose as an energy
source to using fatty acids, reducing the uptake of glucose
by the myocardium.
& Clinical value may be added to a whole-body or torso
FDG PET/CTscan by adding a dedicated brain FDG PET/
CT scan, which may be done on the same injected dose
and in a single session before the whole-body or torso
scan. This can be achieved in a short 5 mm single field of
view (FOV) head acquisition following the guidelines for
acquisition and reconstruction of brain FDG PET/CT
images [39]. The technical qualities of the brain scan as
part of a whole-body FDG PET/CTscan are not sufficient-
ly high for detailed diagnostic purposes. This pertains to
resolution, voxel dimensions, signal to noise ratio, head
fixation issues and possibly reconstruction algorithms.
Thus, a dedicated brain FDG PET/CT scan may be added.
The indications include primarily neurological or psychi-
atric clinical presentations, and suspected paraneoplastic
disease (including limbic encephalitis). Many of these
patients have a negative whole-body or torso FDG PET/
CT scan, and the brain FDG PET/CT scan adds value by
documenting the existence and extent of functional dam-
age or abnormalities (regional inflammatory or epilepti-
form activity, defects following inflammation or from
other conditions). The brain FDG PET/CT scan may help
the differential diagnosis in patients in whom a tumour
cannot be identified (neurodegeneration, toxic encepha-
lopathy, primary neuroinfection). Further, this strategy
allows simultaneous treatment monitoring of activity in
the tumour and paraneoplastic effects in the brain in
tumour-positive patients.
& Clinical experience suggests that proper hydration pre-
vents urinary activity from causing problems in image
interpretation of abdominal/pelvic tumours. If patients
are properly hydrated before imaging, delayed imaging
or furosemide intervention is very rarely necessary. It is
noted that some centres use transurethral catheterisation in
this circumstance but the possible risk of urinary tract
infection needs to be carefully weighed against the poten-
tial benefits of better image quality. In addition, if the
pelvis is a site of particular concern, the CT examination
may be performed first from the head to the pelvis follow-
ed by the emission acquisition in the opposite direction.
This protocol minimises the time delay between the CT
and FDG imaging of the pelvis, and thus there is only
minimal change in bladder volume between the two scans.
& When a diagnostic CT scan with intravenous contrast
agent enhancement is to be performed as part of
the FDG PET/CT study, indications, contraindications
and restrictions have to be assessed by a qualified
physician.
& Medication that interacts with intravenous contrast agent
(e.g. metformin for the treatment of diabetes) and relevant
medical history (e.g. compromised renal function) should
be taken into consideration:
– Renal function should be checked prior to contrast agent
administration in all patients considered at risk of contrast
agent nephrotoxicity. Routine creatinine testing prior to
contrast agent administration is not necessary in all pa-
tients; the major indications are age over 60 years, history
of preexisting renal disease or impairment (including
dialysis, kidney transplant, single kidney, renal cancer
and renal surgery), history of diabetes mellitus, history
of hypertension requiring medical therapy or use of
metformin/metformin-containing drug combinations. Pa-
tients who do not have one of the above risk factors do not
require a baseline serum creatinine determination before
intravenous iodinated contrast agent administration. Esti-
mated glomerular filtration rate is a better predictor of
renal dysfunction than creatinine level alone. Patients
with a high risk of nephrotoxicity are those with creati-
nine >13 mmol/L (1.5 mg/dL) and/or glomerular filtra-
tion <60mL/min. If renal function assessment is required,
a creatinine level and estimated glomerular filtration rate
within the preceding 4 weeks is sufficient in most clinical
settings, although it seems prudent to shorten this interval
for inpatients and those with a new or heightened risk
factor of renal dysfunction [40, 41].
– Metformin is an oral hypoglycaemic agent. If intravenous
contrast agent is going to be administered, metformin
should be discontinued at the time of the procedure and
withheld for 48 h after the procedure. If the risk of
nephrotoxicity is high, metformin can be reinstituted only
after renal function has been reevaluated and found to be
normal. If the risk of nephrotoxicity is low, metformin can
be reinstituted without the need for renal function assess-
ment. An alternative glucose-controlling drug should be
considered during this time [40–42].
– The risk factors for contrast agent-induced nephropathy
must be considered. The more important ones include:
preexisting renal insufficiency, diabetes mellitus, dehydra-
tion or volume depletion, concurrent nephrotoxic drugs,
high dose of contrast agent, age greater than 70 years and
cardiovascular disease. Patients with normal renal function
are at very low risk of contrast agent-induced nephropathy.
Recommendations for preventing contrast agent-induced
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nephropathy in patients at risk include: adequate hydration,
administration of N-acetylcysteine, waiting at least 72 h
between studies with contrast agent and use of iso-osmolar
contrast agent. Discontinuing diuretics, nonsteroidal
antiinflammatory agents and aminoglycosides may also
decrease the risk of contrast agent-induced renal failure
[40, 41].
– Risk factors for adverse reactions to contrast agent must
be assessed. A previous reaction to contrast agent is the
most important of all the risk factors. Adverse reactions
are classified as either idiosyncratic (anaphylactoid) or
nonidiosyncratic. Life-threatening reactions are rare.
Premedication reduces the risk of recurrent anaphy-
laxis, but in patients with a history of a severe
reaction, an unenhanced CT examination is preferred
[40, 41, 43].
– For CT imaging of the abdomen or pelvis, an intraluminal
gastrointestinal contrast agent may be administered to
improve visualisation of the gastrointestinal tract on CT
(unless it is not necessary for the clinical indication or it is
medically contraindicated). Contrast agents must only be
used in accordance with the recommendations given in
section VII. Nowadays, water or water-based contrast
agents are often used as an intraluminal contrast agent
that provides improved image quality with reduced arte-
fact [44]. Water can be an effective contrast agent
allowing better or equal distention in the bowel and better
or equal diagnostic clarity compared with routine barium
contrast agent.
– Some patients have difficulties such as claustrophobia,
dyspnoea or inability to lie still for the duration of the
scan. These patients should be carefully evaluated and an
effort made to solve the problem with minimum conse-
quences for the patient and the quality of the scan; some-
times, however, a solution cannot be found even if the
study is repeated or rescheduled for another day. Occa-
sionally sedatives can be of help in patients suffering
claustrophobia. These issues should be noted in order to





Dosage/activity: Dependent on the system, time per bed
position and the patient’s weight
Administration: Intravenous
Synthesis and quality control: Conform to the European
Pharmacopoeia in Europe or the US Pharmacopeia in the
US
Recommendations for FDG dose and administered activity
Recommendations for FDG administered activity
The minimum recommended administered FDG activity and
PET acquisition duration for each bed position must be ad-
justed so that the product of the FDG activity and PET
acquisition duration is equal to or greater than the specifica-
tions set out below. Therefore, one may decide to apply a
higher activity and reduce the duration of the study or,
preferably, to use a reduced activity and increase the study
duration, thereby keeping ALARA principles in mind as well.
In these guidelines two recommendations are provided for
determining the minimum FDG administered dose in adults,
which assume a linear and a quadratic [45] relationship,
respectively, between PET acquisition time per bed position,
patient weight and recommended FDG activity. Compared
with linear activity prescription, the quadratic scheme
results in a slightly higher administered activity for
patients >75 kg; this compensates for the lower signal
to noise ratio (and hence degraded image quality) due
to excessive attenuation, which occurs when linear ac-
tivity prescription is applied.
The following specifications are given when imaging sites
prefer the use of a linear relationship for pragmatic reasons
(minimum acceptable administered activity recommendation):
1. For systems that apply a PET bed overlap of ≤30 %, the
minimum recommended administered activity is calculat-
ed as follows:
FDG (MBq)=14 (MBq·min·bed−1·kg−1) × patient
weight (kg)/emission acquisition duration per bed posi-
tion (min·bed−1).
2. For systems that apply a PET bed overlap of >30 %, the
minimum FDG administered activity is calculated as fol-
lows:
FDG (MBq)=7 (MBq·min·bed−1·kg−1) × patient
weight (kg)/emission acquisition duration per bed posi-
tion (min·bed−1).
Alternative: This alternative includes using a quadratic
relationship between recommended administered FDG activ-
ity, weight and duration of emission acquisition [45]. In this
case use the above equations to determine the administered
activity for a 75 kg patient. Next, multiply this activity by the
square of the patient weight/75. This will provide the mini-
mum administered activity.
1. For systems that apply a PET bed overlap of ≤30 %, the
minimum administered FDG activity is calculated as fol-
lows:
FDG (MBq)=1,050 (MBq·min·bed−1·kg−2) × (patient
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weight (kg)/75)2/emission acquisition duration per bed
position (min·bed−1).
2. For systems that apply a PET bed overlap of >30 %, the
minimum FDG activity is calculated as follows:
FDG (MBq)=525 (MBq·min·bed−1·kg−2) × (patient
weight (kg)/75)2/emission acquisition duration per bed
position (min·bed−1).
Specific notes and pitfalls to be considered:
& An exploratory further optimisation is presently being
evaluated by EARL [46, 47]. This procedure would allow
lowering the administered FDG activity for PET/CT sys-
tems with higher sensitivity or improved performance
using new enhanced technology (e.g. better time-of-
flight performance, continuous bed motion or extended
axial FOV, i.e. length of bed position). A prerequisite is
that imaging sites first obtain EARL accreditation for that
system and subsequently follow the instructions provided
by the standard operating procedure (SOP) “EARL pro-
cedure for assessing PET/CT system specific patient FDG
activity preparations for quantitative FDG PET/CT stud-
ies” [47].
& A short emission acquisition duration per bed position
could also be balanced by a higher administered FDG
activity [48, 49].
& For patients weighing more than 90 kg, increasing the
emission acquisition time per bed position rather than
increasing the administered FDG activity is recom-
mended to improve image quality. Literature suggests
that FDG activities higher than 530 MBq for patients
above 90 kg should not be applied for L(Y)SO systems
[50].
& A maximum administered FDG activity may be imposed
by national law. If this is the case, increasing the emission
acquisition time should be pursued to keep administered
FDG activity within legal limits.
& If the PET acquisition duration for each bed position
can be set separately, then the acquisition duration per
bed position may be further reduced by up to 50 % for
bed positions outside the thorax and abdomen (i.e. at
the level of the head, neck and legs) because overall
attenuation in these body regions is lower. The FDG
activity must still be calculated assuming the acquisition
duration per bed position as used for bed positions at
the level of the thorax and abdomen. Systems with
continuous motion functionality may increase motion
speed twofold outside the thoracic and abdominal
regions.
& In all cases the administered FDG activity should not
result in activities within the FOV that exceed the peak
count rate capability of the PET/CT system in use. The
emission acquisition duration should then be increased to
keep image quality within acceptable limits.
For children and adolescents, administered FDG activity
should adhere to the EANM or SNMMI recommendations on
paediatric radiopharmaceutical administration [51, 52] or na-
tional activity limits, if national limits are lower. Furthermore,
there are specific guidelines for FDG PET/CT in paediatric
oncology [22].
Materials for preparation and administration of FDG
and contrast agent
The following materials and set-up are recommended:
& Weighing scales that are accredited and checked at least
annually. Scales should be accurate to within 1 kg.
& Equipment for measuring height, which should be accu-
rate (to within 0.5 cm) and maintained regularly.
& Bedside glucose meter to check serum glucose. Note that
many bedside methods do not have sufficient precision to
be used for SUV glucose correction [29].
& A three-way valve system for administering FDG and
flushing with physiological saline is usually used. How-
ever, if automated bedside administration systems are
used, then other types of lines may be required to obtain
the same flushing and administration results.
& A programmable fluid injector with at least two fluid
containers for intravenous administration of contrast
agent. Only if a fluid injector is not available may intra-
venous contrast agent be injected manually, although two-
phase contrast agent protocols cannot be carried out.
& First-line emergency drugs and equipment should be in
the examination room when a diagnostic CT scan with
intravenous contrast agent is to be performed [43]. Emer-
gency devices and drugs are to be available according to
national and hospital procedures.
& In the case of manual administration:
– An indwelling intravenous device is used to administer
the FDG once the blood glucose has been determined.
Make sure that if there is a needle on the syringe it is free
of FDG.
– Flush and rinse out the administration syringe with at
least 10 mL of normal saline (NaCl 0.9 %) – or solutions
without glucose – using the three-way valve.
& In the case of automated administration:
– Make sure that the automated system is able to administer
a net FDG activity within 3 % accuracy (this must be
ensured by the manufacturer and verified by the user), i.e.
the actual administered activity may not deviate by more
Eur J Nucl Med Mol Imaging (2015) 42:328–354 337
than 3 % from that indicated by the device. Follow the
instructions provided by the manufacturer.
Procedure for preparation and administration of FDG
and contrast agent
& Report any problems with FDG administration and image
the injection area if extravasation is suspected.
& The administration system and/or administration lines and
intravenous access can be removed after tracer adminis-
tration (unless CT contrast agent is to be administered
subsequently by intravenous injection).
& Residual activity in administration lines and intravenous
access should be measured in order to derive net admin-
istered FDG activity; procedures and recommendations
are detailed in the UPICT oncology FDG-PET CT proto-
col [30].
& Ambient conditions of the waiting room should help cre-
ate a stress-free environment and a warm temperature.
Give the patient extra blankets if necessary.
& Ask patients to lie or sit as calmly as they can, and not to
talk. Provide comfortable beds or chairs. They may go to
the toilet while waiting, preferably more than 30 min after
injection. Ask patients to use the bathroom to empty their
bladder 5 min before the start of the FDG PET/CT study.
& When dedicated brain imaging is indicated, additional
preparation is necessary [39]. Patients should be posi-
tioned comfortably in a quiet, dimly lit room several
minutes before FDG administration and during the uptake
phase of FDG (at least 20 min). They should be instructed
not to speak, read or be otherwise active. If possible,
they should keep their eyes closed during the uptake
phase of FDG. It is desirable to have the cannula for
intravenous administration in place 10 min before FDG
administration.
& Intense bladder or ureter activity can impair the interpre-
tation of lesions in the pelvis and retroperitoneum. There-
fore, during the waiting period patients may be asked to
drink another 500 mL of water. If a patient is unable to
hydrate orally, this amount can be given in the form of
normal saline intravenously, provided such a fluid load is
not medically contraindicated, e.g. due to impaired renal
function or poor cardiac function. Loop diuretics (e.g.
intravenous furosemide) can occasionally be given, al-
though this is rarely necessary.
& The recommended interval between FDG administration
and the start of acquisition is 60min. However, for clinical
trials this may differ depending on the disease and the
aims of the study. Any such variation should be clearly
stated in the study protocol. The actual interval should be
recorded, i.e. the time between FDG injection and imaging
should be reported. Be aware that this is usually not equal
to the FDG activity assay or calibration time. Note that
consistency of SUV measurements (in-house and when
compared to the literature) depends on strict observance of
the uptake time, and therefore a 60 min interval is recom-
mended with an acceptable range of 55 – 75 min [30].
When repeating an FDG PET/CT study in the same pa-
tient, especially in the context of therapy response assess-
ment, it is essential to apply the same uptake interval to
within 10 min [30]. In addition, the use of the same PET/
CT system and identical acquisition and reconstruction
settings should be applied when making multiple exami-
nations in the same patient.
Protocol/image acquisition
PET acquisition protocol
& Axial anatomical scan coverage: For most oncology
indications covering the range from the base of the skull
to the mid-thigh is sufficient. A longer scanning trajec-
tory of the whole body may be used if appropriate.
Extended whole-body examinations are performed in
patients with tumours that show a high probability of
metastases in the head, skull, brain and lower extremi-
ties. In patients with tumours with a high risk of head
and brain metastasis but not metastasis in the lower
extremities (e.g. lung cancer), it may be appropriate to
perform an extended torso FDG PET/CT scan including
the brain in the same scan [53]. Limited-view tumour
imaging can be considered for follow-up examinations
if the disease is restricted to a defined region (e.g.
solitary pulmonary nodule, suspicion of lung cancer,
examination of hilar lymph nodes, head and neck tu-
mours, assessment of therapy response). If limited-view
imaging is performed in the setting of a longitudinal
study, the uptake time of the lesion being studied should
be the same (to within 5 min) across all longitudinal
imaging studies in the same patient.
& Generally, the patient should be positioned with the
arms elevated and supported above the head to avoid
beam-hardening artefacts in the abdominal and pelvic
regions as well as artefacts caused by truncation of the
measured FOV. If the patient is not able to keep the
arms elevated above the head, one arm can be kept
above the head with the other positioned alongside the
body, or both arms can be positioned alongside and
close to the body. Either way, every attempt should be
made to avoid CT truncation. When using systems
with extended CT FOVs, the arms may be positioned
alongside the body to enhance patient comfort provi-
ded CT truncation is avoided.
338 Eur J Nucl Med Mol Imaging (2015) 42:328–354
& For examination of head and neck tumours a two-step
protocol may be helpful [54]:
1. Head and neck portion with the arms down, then
2. Apex of the lung through the mid-thigh with the arms
up.
& If the FDG PET/CT data are used for radiation planning,
the examination should be performed in the position used
for radiotherapy treatment, employing the same dedicated
positioning devices as are used in the radiotherapy
department (e.g. the same radiotherapy table top, laser
alignment, immobilisation devices and measures) [15].
These guidelines consider static acquisitions only.
Radiotherapy planning may increasingly require respi-
ratory gating, too, but this is not covered in the present
guidelines.
& When dedicated brain imaging is indicated [39]:
– Patient preparation should be as for brain scan [39]
– Arms down, head fixed in a head holder
– CT topogram of head, followed by
– Low-dose CT scan, followed by
– Single FOV PET acquisition
– 5 min acquisition 45 – 50min after injection with injected
doses of 300 – 400 MBq. If the suspected underlying
indication for the brain scan is probably not cancer-
related (dementia, etc.), the emission scan can be acquired
earlier, up to 30 min after injection. However, identical
time frames must be used for the same indications to
render the results comparable.
– Arms down followed by one of the protocols described in
the next section (CT protocols for the FDGPET/CTstudy).
– Brain image reconstruction performed independently for
body scan following guidelines.
& In general, FDG PET/CT is performed using a protocol
comprising a scanogram/scout scan/topogram and a low-
dose CT scan for attenuation correction (CT-AC) and
anatomical correlation.
& The CT-AC scan should be performed while the patient
continues tidal or shallow breathing. In the case of CT
systems with six or fewer rings, a protocol using breath
hold in normal expiration should be considered for the
duration of scanning the thorax and upper abdomen.
& A standard diagnostic CT scan with intravenous contrast
agent may, if appropriate, be performed. Several strategies
for performing PET/CT studies that include diagnostic CT
imaging are provided in detail below.
& Images should be reviewed before the patient leaves
the department to ensure that the examination is tech-
nically satisfactory (i.e. that the clinical question can
be addressed properly) and to assess any need for
additional imaging or urgent contact with the referring
physician.
& Online random correction should be based on the ‘delayed
coincidence time window’ technique or random correction
using a model based on (block) singles count rates.
& During patient registration with the PET/CT system, users
should carefully enter all information into the PET/CT
console correctly. This includes, but may not be limited
to, patient height and body weight, radiopharmaceutical
and the net activity administered. Also the assay activity
(i.e. FDG activity) and assay time (i.e. activity calibration
time) should be noted and reported. In addition, the time of
injection (usually not equal to the assay time or activity
calibration time) should be noted and reported. If this
information cannot be entered into the PET/CT system,
it should be reported in the patient or scan report file.
& Decay correction must be ‘on’ (see also section PET
image reconstruction).
CT protocols for the FDG PET/CT study
& CT imaging within the framework of FDG PET/CT stud-
ies typically consists of a topogram and a single or multi-
ple helical CT scans.
& CTacquisition parameters (e.g. tube current, voltage, slice
thickness, rotation time and pitch) should be chosen with
regard to the objective of the CT examination (e.g. atten-
uation and scatter correction, colocalisation of radiologi-
cally equivalent interpretation). Specific local or national
dose limits may apply for these types of CT examinations
and should always be adhered to. Overall, CTscan param-
eters should be chosen such that patient exposure is
minimised yet dose is adequate to obtain the necessary
diagnostic information.
& Ultra low-dose CT scans are now being introduced on
some PET/CTsystems, often in combination with iterative
reconstruction methods (as discussed below), which may
be applied to further reduce CT radiation dose.
& For a diagnostic contrast-enhanced CT scan, standard CT
settings as suggested by related guidelines and the super-
vising radiologist or responsible physician should be
employed. Modulation of the tube current is encouraged
in the absence of metallic implants (e.g. orthopaedic
braces) in the coaxial imaging range to lower patient
exposure. Depending on the clinical question, intravenous
and/or oral contrast agents may be employed. It might be
appropriate to perform a diagnostic CT scan for particular
regions of the body, followed by a low-dose CTscan of the
rest of the body for CT attenuation correction and
colocalisation. In some instances, it might be preferable
to begin with a low-dose CT scan of the body and then
decide to add a diagnostic CT scan of a particular region,
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as the findings on the low-dose CT scan may influence the
need for a contrast-enhanced or higher resolution regional
view.
& High intravenous or intestinal concentrations of contrast
agent may cause artefacts in the reconstructed PET images
following CT attenuation correction and thus affect quan-
tification. The impact of intravenous contrast agents on the
accuracy of attenuation correction is considered accept-
able when CT data are collected in the equilibrium or
venous phase (i.e. delayed acquisition) and in some cen-
tres a contrast-enhanced CT scan only is performed, al-
though uptake in reference regions such as the mediasti-
num and liver may be affected.
& Arterial phase CTacquisitions should be avoided. In FDG
PET/CT studies without the need for advanced quantifi-
cation, intravenous contrast agents may be used directly
(i.e. the CT scan can also be used for attenuation correc-
tion) during the FDGPET/CTstudy because the impact on
visual image quality and interpretation is modest. Howev-
er, deep inspiration for chest CT acquisition will cause a
large degree of misregistration and may introduce unac-
ceptable artefacts if the low-dose CT scan (with normal
breathing) is replaced by such a diagnostic deep inspira-
tion CT scan.
& Deep inspiration chest CT scans should not be used for
attenuation correction when PET quantification is re-
quired or intended. Therefore, for attenuation correction,
the PETstudy ideally should be combinedwith a low-dose
CTscan obtained during tidal or shallow breathing or with
a contrast-enhanced CT scan obtained during tidal or
shallow breathing (as described below).
& The presence of a positive contrast agent (intravenous or
oral) may minimally affect the CT attenuation map and,
therefore, affects SUV quantification [55]. If this were the
only aspect to be taken into consideration, the ideal would
be to prohibit CTcontrast agent administration. However, in
some clinical situations (depending upon tumour type, tu-
mour behaviour or level of anatomical interest), the benefit
of CTcontrast agentsmay outweigh the small errors induced
in SUV measurement, which may include increased SUV
variability. Each protocol should specify the desired ap-
proach for the given study. Most importantly, in the same
subject, the same approach should be followed at all subse-
quent imaging time points. In the case of longitudinal studies
in which a diagnostic contrast-enhanced CTscanmay not be
indicated in all PET/CT examinations, strategies 1, 2a and
2b, as indicated below, should be followed.
& If the FDG PET/CT study is performed with the purpose
of quantitatively assessing FDG uptake and a diagnostic
CT scan is required, the following PETand CTacquisition
sequences or strategies should be followed, as indicated in
the UPICT Oncology FDG PET/CT protocol [30] and the
FDG PET/CT QIBA profile [56]:
– Strategy 1: When CT is used for attenuation correction
and localisation only (not intended as a clinically diag-
nostic CT scan):
& CT topogram, followed by
& Low-dose CT scan, followed by
& PET acquisition
– Strategy 2: When a contrast-enhanced diagnostic CTscan
is also needed, one of the following options must be used:
Strategy 2a (recommended as it avoids any, albeit possi-
bly minimal, impact of intravenous contrast enhance-
ment on attenuation correction and therefore SUV
determination):
& Follow strategy 1
& Acquire an additional intravenous contrast-
enhanced diagnostic CT scan with breathing in-
structions, if needed
Strategy 2b:
& Perform an intravenous contrast-enhanced diag-
nostic CT scan with breathing instruction if
needed
& Follow strategy 1with a delay of at least 60 s to allow
contrast agent to dilute over the body/blood pool
& In the case of protocols or scanning strategies that can
be used in clinical practice, i.e. when there is no need
for or intention to perform SUV-based quantification,
the diagnostic CT scan with intravenous contrast agent
may be used for attenuation correction. If contrast-
enhanced CT is used for attenuation correction it
may alter SUV quantification (<10 % on average).
Therefore, the strategies below are for image interpre-
tation based on visual (uptake) assessment only. FDG
PET/CT studies performed with the intention of
assessing FDG uptake quantitatively should follow
the recommendations given above (strategy 1, 2a or
2b). A deep-inspiration thoracic CT scan with a 20 s
delay from the beginning of contrast agent infusion
can be included as it will provide additional informa-
tion. However, this CT scan is used neither for atten-
uation correction nor for PET/CT image fusion, but
rather to assess the lung parenchyma with thinner
slices (2.5 mm), which is very useful for comparison
with previous and/or future studies, and also allows
evaluation of thoracic vessels.
– Strategy 3 (low-dose CT scan):
& CT topogram, followed by
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& A deep-inspiration thoracic CT scan with a 20 s delay
from the beginning of the contrast agent infusion (this
CT scan is used neither for attenuation correction nor
for PET/CT image fusion), followed by
& Awhole-body low-dose CTscan (with shallow or tidal
breathing) with a 45 s delay after the thoracic CT scan
(equilibrium or venous phase) if the thoracic CT scan
was performed or with a 60 s delay after the beginning
of contrast agent infusion if the thoracic CT was not
performed, followed by
& PET acquisition
– Strategy 4 (diagnostic CT scan):
& CT topogram, followed by
& A deep-inspiration thoracic CT scan with a 20 s delay
from the beginning of contrast agent infusion (this CT
scan is used neither for attenuation correction nor for
PET/CT image fusion), followed by
& A whole-body diagnostic CT scan (with shallow
breathing) with a 45 s delay after the thoracic CT scan
(equilibrium or venous phase) if the thoracic CT scan
was performed, or with a 60 s delay after the beginning
of contrast agent infusion if the thoracic CT scan was
not performed, followed by
& PET acquisition
& Other specific protocols can be applied depending on the
tumour type and the clinical indication.
& Intravenous contrast agent is ideally administered with a
programmable fluid injector at a speed of 2.5 ml/s for a
catheter of 20G×1.16″ if located in the elbow. If the
catheter is placed in other locations, the diameter of the
catheter and/or the speed of infusion and delay may need
to be adjusted.
& Oral contrast agents allow better delineation of the gastro-
intestinal tract. A positive contrast agent (for example
diluted barium) as well as a negative or water-based
contrast agent (for example water or locust bean gum)
can be used [44]. High intraluminal concentrations of
barium or iodinated contrast agents can cause an attenua-
tion correction artefact in PET images, resulting in an
overestimation of FDG accumulation at those sites. These
artefacts can be avoided by using a negative contrast
agent. However, administration of water only as a nega-
tive intraluminal contrast agent itself is associated with
fast reabsorption and can cause increased nonspecific
FDG accumulation in the bowel [57]. If quantification of
the FDG PET/CT studies is required, the use of diluted
positive contrast agents only is recommended. The con-
centration of diluted positive contrast agents should be
low enough to guarantee absence of attenuation correction
artefacts, and this should be verified for each combination
of PET/CT system, PET/CT image reconstruction soft-
ware and contrast agent being used.
& It should be ensured that the patient is lying within the CT-
AC FOV and in the same position as during the PET
acquisition. If the system is equipped with extended
FOV capabilities this option should preferably be used to
avoid CT truncation.
& Metal implants can cause severe artefacts in the CT image.
Metal artefact reduction techniques may be used to mini-
mise these artefacts. When the CT data are used for
attenuation correction of the PET data, it should be con-
sidered that even when using metal artefact reduction
techniques, metal implants will likely result in reduced
PET image quality and will prevent proper quantification
(at and near the metal implant). FDG uptake should be
confirmed by inspecting the PET images without attenu-
ation correction.
Pitfalls
& In most PET/CTsystems today, themeasured FOVof the CT
scanner is smaller than that of the PET scanner. Truncating
the CT images causes reconstruction artefacts and thus inac-
curate quantification of the PET study. When available,
truncation correction algorithms may be applied during im-
age reconstruction (and/or during processing of the CT data
used for attenuation correction). As the amount of truncation
may vary across studies and subjects, it will be difficult to
ensure proper quantification across studies and subjects. It is,
therefore, strongly recommended that any truncation of the
CT images is avoided. If available, the use of extended CT
and PET FOVs is recommended. It should be noted that
truncation of the CT images may occasionally seriously
affect scatter correction scaling as well, and may lead to
inaccurate quantitative results.
& Make sure that all clocks (including the dose calibrators –
the one at the hospital and the one at the external labora-
tory dispensing the FDG – and the PET/CT system) are
synchronised and that this is regularly checked. Consult
the local service engineer when needed. Clocks should be
synchronised with the official local time to within 1 min
(in the case of studies using 18F).
Image reconstruction
PET image reconstruction
The PET emission data must be corrected for geometrical
response and detector efficiency (normalisation), system dead
time, random coincidences, scatter and attenuation.
& All the corrections necessary to obtain quantitative image
data should be applied during the reconstruction process.
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& During image reconstruction, matrix sizes and zoom fac-
tors should be chosen such that reconstructed voxel sizes
are within 3.0 – 4.0 mm in any direction [30, 56].
& When available, time-of-flight information should be used
during reconstruction.
& Resolution modelling during reconstruction or other new
reconstruction or image processing methods may be ap-
plied. In the case of multicentre studies or when quantifi-
cation is required, the use of these methods typically
entails additional filtering during or after image recon-
struction in order to meet the standardised/harmonised
quantitative PET/CT system performance specifications,
as detailed below. When these multicentre standards can-
not be met, these reconstruction methods and settings
should not be used for quantification of FDG uptake.
& Spatial filters applied during or after reconstruction should
not exceed a full-width at half-maximum of 7 mm, not even
to mitigate Gibbs artefacts when using resolution model-
ling. In these cases the use of reconstructed images gener-
ated without resolution modelling should be considered.
It is good clinical practice to perform reconstructions with
and without attenuation correction to identify potential recon-
struction artefacts caused by the CT-AC. Both attenuation-
corrected (AC-PET) and non-attenuation-corrected PET
(NAC-PET) images should be available for interpretation
and lesions seen on the AC-PET images may need to be
checked on the NAC-PET images, particularly when adjacent
to highly attenuating materials, such as contrast agent or metal
implants.
Further standardisation of reconstruction settings is neces-
sary to obtain standardised and harmonised SUV recoveries.
This requires reconstruction settings to be chosen so as to
achieve matching convergence and spatial resolution across
various systems and sites, especially within a multicentre
setting [48, 58, 59]. These reconstruction settings should thus
be chosen to meet the multicentre QC harmonising specifica-
tions for both calibration QC and image quality/SUVrecovery
QC, for example as described on the EARL website [46].
Indicative reconstruction settings for each system type are
provided on request through the EARL website [46].
It may be appropriate to perform multiple PET reconstruc-
tions with different reconstruction settings. For quantitative
assessment of the FDG PET/CT study, the EARL-approved
reconstruction settings, which meet the standardised perfor-
mance standards, should be used. An additional reconstruc-
tion designed for optimal visual assessment may be performed
for qualitative interpretation only. This reconstruction may be
performed, for example, in order to maximise lesion detect-
ability or to meet local preferences for visual interpretation of
the FDG PET/CT study, as was suggested and demonstrated
by Lasnon et al. [60]. Similar strategies may be applied for
different PET/CT systems as well, provided quantitative
interpretations/analyses are performed using the EARL-
approved reconstruction settings.
CT image reconstruction
For diagnostic CT scans, acquisition parameters should be
determined according to specific or national radiology society
guidelines. The CT data that are acquired during the PET/CT
study are usually reconstructed using filtered back projection.
Recently introduced iterative reconstruction methods for CT
data may be applied, if available on the PET/CT system.
Depending on the CT protocol and the clinical case, separate
CT reconstructions may be performed for diagnostic purposes
and CT-AC. The reconstructions will probably differ in their
slice thickness, slice overlap, filter etc. In addition to the
reconstruction kernel that modulates the image characteristics
within the slices (i.e. spatial resolution, edge enhancement and
noise texture), a longitudinal filter in the z-dimension is often
used to optimise the resolution in the axial direction and to
modify the slice sensitivity profiles. The measured attenuation
values (μ) are normalised to the density of water (μwater) in
order to assign a device-independent numerical value in the
framework of the reconstruction:
CT value = Hounsfield units = 1,000(μ − μwater)/μwater
In modern CT systems the spatial resolution in the z-direc-
tion is almost as high as the transaxial resolution and nearly
isotropic, allowing high-quality images in the coronal and
sagittal views. Additionally, postprocessing such as volume
rendering or maximum intensity projections benefit from
using the high-quality reconstructed CT data.
Image analysis and interpretation
Image analysis and SUV calculations
FDG PET images should be displayed with and without atten-
uation correction.On all slices (of the attenuation-corrected data)
quantitative information with respect to size and FDG uptake
can be retrieved. Imagesmust be evaluated using software that is
able to display fused PET and CT data and use an SUV scale.
Monitors used for image viewing should be approved for clin-
ical use in radiology and nuclear medicine. Characteristics and
settings of the monitor should be in line with published stan-
dards (e.g. the Medical Electrical Safety Standards, IEC 60601-
1/EN 60601-1; the Medical ECM Standards, IEC 60601-1-2,
EN 60601-1-2; or national guidelines). Moreover, viewing con-
ditions (e.g. background light) must be appropriate to ensure
adequate image inspection. Image data should be stored on an
approved PACS system and in DICOM format; further details
and recommendations regarding image data format can be found
in the QIBA FDG PET/CT profile [56].
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The presence or absence of abnormal FDG accumulation
on the PET images, especially focal accumulation, in combi-
nation with intensity of uptake and anatomical size should be
evaluated. Absence of tracer accumulation in anatomical ab-
normalities seen on the CT scan or other imaging may be
particularly significant. When appropriate, the report should
correlate PET/CT findings with those of other diagnostic tests,
interpret them in that context and consider them in relation to
the clinical data. For response assessment, the images should
be viewed over the same dynamic grey scale or colour scale
range, i.e. a fixed colour scale; for example, from SUV=0 to
SUV=10 using an inverse linear scale.
Both uncorrected and attenuation-corrected images may
need to be reviewed to identify artefacts caused by contrast
agents, metal implants and/or patient motion. In clinical trials,
criteria for visual analysis should be defined a priori within the
study protocol.
SUV is increasingly used in clinical studies in addition to
visual assessments. SUV is a measurement of the uptake in a
tumour normalised on the basis of a distribution volume. Most
of the published literature relates to SUV (normalised to body
weight) measurements. SUV normalised to lean body mass
(LBM) is referred to as SUL [61], and is a recommended
quantitative measure of FDG uptake. SUL should
preferably be calculated alongside SUV, as follows:
SUL = ActVOI (kBq/mL)/Actadministered (MBq)/LBM (kg)
The following calculation is applied in the case of plasma
glucose correction:
SULglu = ActVOI (kBq/mL) × Glucplasma (mmol/L)/
Actadministered (MBq)/LBM (kg) × 5.0 (mmol/L)
where ActVOI is the activity concentration measured in the
volume of interest (VOI) and Actadministered is the net admin-
istered activity corrected for the physical decay of FDG to the
start of acquisition and corrected for the residual activity in the
syringe and/or administration lines and system. LBM is cal-
culated according to the formula of Janmahasatian et al. [62]:
LBMM = 9,270 × weight/(6,680 + 216 × BMI)
LBMF = 9,270 × weight/(8,780 + 244 × BMI)
where LBMM and LBMF are the LBM for males and
females, and BMI is body mass index (weight/height2),
and weight and height are in kilograms and metres, respec-
tively. These formulas are clearly more realistic than the
previously used James formulas [63, 64], which fail at
weights greater than about 120 kg [65]. Patient height,
weight and gender should be reported to allow other SUV
normalisations, such as weight and body surface area. In
these cases LBM is replaced by body weight and body
surface area, respectively, in the SUL equations given
above.
The use of SUL is preferred for response assessment stud-
ies when large changes in body weight may occur during the
course of the treatment. As stated above, it is recommended
plasma glucose levels be measured using validated method-
ology and that SUL be calculated with and without plasma
glucose correction in all response monitoring studies. Note
that the measured glucose content (Glucplasma) is normalised
for an overall population average of 5.0 mmol/L so that the
SULs with and without correction for glucose content (SULglu
and SUL, respectively) are numerically practically identical
(on average) [49].
Physiological FDG distribution and interpretation criteria
Accumulation of FDG can normally be seen in the brain,
heart, kidneys and urinary tract at 60 min after injection
[66]. The brain has a high uptake of FDG (about 7 % of
injected activity). The myocardium in a typical fasting state
primarily uses free fatty acids, but after glucose load it uses
glucose. In the fasting state, FDG uptake in the myocardium
should be low, but this is variable. Unlike glucose, FDG is
excreted by the kidneys into the urine and accumulates in the
urinary tract. There is some degree of FDG accumulation in
muscles that can be increased following exercise and serum
insulin. Uptake in the gastrointestinal tract varies from patient
to patient and may be increased, for example, in patients
taking metformin. Uptake is common in lymphoid tissue in
Waldeyer’s ring and in the lymphoid tissue of the terminal
ileum and caecum. Physiological thymic uptake may be pres-
ent, especially in children and young adults. Uptake in brown
fat may be observed more commonly in young patients and
when the ambient temperature is low. No physiological uptake
is noted in bone itself (unless free 18F-fluoride is present as a
contaminant), but bone marrow uptake can be present to a
variable degree in patients receiving growth factors (granulo-
cyte colony-stimulating factor, G-CSF, and granulocyte mac-
rophage CSF, GM-CSF) as well as in patients with marrow
proliferation for other reasons such as infection, inflammation
or anaemia, and following chemotherapy.
& Due to the high physiological FDG uptake in the brain,
FDG PET/CT is of limited value for detection of brain
metastases. Consequently, FDG PET/CT is generally not
used for the primary detection or exclusion of brain
metastases.
& Increased FDG uptake is observed in many neoplastic
lesions, granulation tissue (e.g. wound healing), infections
and other inflammatory processes. A detailed description of
pitfalls and situations that can lead to false-positive (benign
processes that can show FDG uptake) or false-negative
FDG PET/CT interpretation has been published [67].
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& Patterns of FDG uptake, established CT morphological
criteria and correlation with patient history, physical ex-
amination and other imaging modalities may be helpful
for differentiation between malignant and benign lesions.
& SUVs and related quantitative measures, such as metabol-
ic tumour volume (MTV) and total lesion glycolysis
(TLG), have gained increasing importance for therapy
response monitoring [30, 61, 68] and for prognostic as-
sessment [5, 69–71].
& There is no single lower limit of the intensity of FDG
uptake for the detection of abnormal uptake within lesions
as it depends on the degree of contrast between the tumour
and its immediate surroundings. This contrast is related to
several pathophysiological factors, the most significant of
which are histology (FDG avidity of the type of tumour),
volume of vital tumour cells, movement during static
acquisition (e.g. blurred signals in the case of pulmonary
foci) and physiological high uptake in adjacent back-
ground. Furthermore, the sensitivity of FDG PET/CT
may be reduced in diabetic patients with elevated glucose
levels [72].
& Although there are no conclusive data on the optimum
interval between chemotherapy and FDG PET/CT, an
interval of at least 10 days between the last treatment
and the FDG PET/CTexamination is generally considered
adequate for measurement of response [20]. This is be-
cause of the balance between any possible effects on
tumour metabolism (such as macrophage impairment)
and systemic effects (such as bone marrow activation
following bone marrow depression, which may or may
not be caused by growth factors). If an interval of 10 days
is not possible, FDG PET/CTshould be delayed as long as
possible after the previous chemotherapy administration
(i.e. until as close as possible to the next treatment cycle).
& The effects of growth factors (G-CSF and GM-CSF) on
FDG biodistribution (due to enhanced bone marrow up-
take) generally last for more than 2 weeks after the final
administration [20].
& It is assumed that the (side) effects of radiotherapy are
longer-lasting; investigation of patients with head and
neck carcinoma treated with radiation have shown that
radiation-induced inflammation can be seen on the FDG
PET/CT images for 2 – 3 months after the end of treatment
[73, 74]. Waiting 2 or 3 months following completion of
radiation therapy before obtaining a PET/CT scan is clin-
ically appropriate as patients rarely develop clinical prob-
lems in the first 3 months after treatment.
& In patients who have undergone surgery, uptake de-
pends on the extent of surgery, the presence of
infection/inflammation in the wound, and how long
after surgery images are acquired. For example, there
are few visible signs of a mediastinoscopy after
10 days but sternotomy signs will remain visible for
months. Following surgery, it is recommended to de-
lay the FDG PET/CT for at least 6 weeks due to
postsurgical inflammation if the scan is primarily be-
ing done to assess the surgical field.
& FDG PET/CT for diagnostic purposes is generally
assessed using visual criteria, looking for focally increased
uptake that may represent malignancy in the appropriate
clinical context. It is unclear how SUV can contribute to
patient assessment, partly because of the considerable
variability in the methodology used. However, this docu-
ment and several others propose harmonised quantitative
FDG PET/CT imaging procedures in multicentre studies
and harmonised quantitative interpretation criteria to as-
sess treatment response [30].
Documentation and reporting
The report is the main mode of communication between the
physician interpreting the imaging study and the referring
physician, and frequently leads to relevant changes in patient
management [75]. The SNMMI has recently published
reporting recommendations for oncological FDG PET/CT
imaging [76].
Direct communication
Abnormalities of immediate clinical importance should be
directly or verbally communicated to the appropriate health-
care provider if a delay in treatment might result in significant
morbidity. An example of such an abnormality would be a
lesion with a high risk of pathological fracture. Other clinical-
ly significant unexpected findings should also be communi-
cated verbally. Reporting of abnormalities requiring urgent
attention should be consistent with the policy of the
interpreting physician’s local organisation.
Written communication
Written documentation of verbal reporting should be made in
the medical record, usually as part of the PET/CT report [75,
76].
Contents of the report
Study identification
The report should include the full name of the patient, medical
record number and date of birth. The protocol name of the
examination should also be included, as well as the date and
time of its performance. The electronic medical record usually
provides these data, as well as a unique study number.
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Clinical information
At a minimum, the clinical history should include age, gender,
weight, height, reason for referral and the specific question to
be answered. If known, the diagnosis and a brief treatment
history should be provided. The results of relevant diagnostic
tests and prior imaging findings should be summarised. Infor-
mation relevant for reimbursement should also be included.
Procedure description
The type and date of comparison studies should be stated. If
no comparison studies are available, a statement should be
made to that effect.
Blood glucose level before FDG administration should be
documented.
Study-specific information should include the radiophar-
maceutical, the amount of injected activity in megabecquerels
and/or millicuries, the route of administration (intravenous)
and the date and time of administration. The anatomical site of
administration is optional, but should be recorded. The name,
dose and route of administration of regulated nonradioactive
drugs and agents should also be stated. The type of PET/CT
system should be specified, but specific equipment informa-
tion is optional.
A description of the procedure should include the time the
patient was examined or the time interval between adminis-
tration of FDG and the start time of the acquisition. The part of
the body that was covered should be described from the start
to the end point. The position of the patient (supine or prone)
and the position of the arms (elevated or by the sides) should
be stated if nonstandard.
Description of the CT part of the examination may be
limited to a statement that a low-mAs CT was performed for
attenuation correction and anatomical registration of the emis-
sion images. However, findings should be reported. If the CT
examination was optimised for diagnosis, then a more com-
plete description of the CT protocol and anatomical findings
should be provided. Dosimetric parameters should be includ-
ed as required by regulations; here, DICOM structured reports
may facilitate the extraction of the relevant dose information.
The report should state whether CT with or without CT
contrast agent was used for CT attenuation correction.
Routine processing parameters are usually not stated in the
report, but any special circumstances requiring additional
processing, such as motion correction, should be described.
Description of the findings
It is good practice to provide a structured report with concise
concluding statements intended to answer the specific clinical
question(s) posed, if possible. Nevertheless, there is great
variation in the style of reporting. Recommendations with
regard to biopsy, alternative radiological studies and follow-
up should also be included in the conclusion as appropriate
[77]. The interpretation provided by an imaging physician is
the chief manifestation of the physician’s expertise. Its content
affects patient management and clinical outcomes, and it is
also a legal document [76].
& Quality of the FDG PET/CT study, e.g. limited due to
motion artefacts, abnormal biodistribution of tracer
(FDG accumulation in muscles and/or brown fat),
infiltration of tracer at the injection site or hyper-
glycaemia. CT-related artefacts should also be men-
tioned such as metallic artefacts and other information
on large patient body habitus when the quality of the
study is affected.
& Description of the location, the extent and the intensity
(SUV and/or SUL) of pathological FDG accumulation
related to normal tissue.
& Description of relevant findings on CT and their relation-
ship to pathological FDG accumulation. FDG uptake may
be reported as mild, moderate or intense and compared to
the background uptake in, for example, the liver paren-
chyma (mean SUV 2.0 – 3.0, maximum SUV 3.0 – 4.0).
However, criteria for visual interpretation need to be de-
fined for each study protocol and may vary according to
the type of cancer and for different tumour locations.
Some criteria have already been proposed [78, 79]. Inci-
dental FDG PET and CT findings should be included in
the report, particularly if they are of clinical relevance.
& The CT part of the FDG PET/CT report must describe all
relevant anatomical findings (some of which may be FDG
PET-negative).
& Limitations: If necessary, confounding factors that might
influence the sensitivity or specificity of the FDG PET/CT
study may be mentioned such as small lesions (partial
volume effect), inflammatory changes, muscle activity,
high blood glucose levels at the time of injection,
paravascular infiltration of FDG or tissue injections.
& Clinical context: In the body of the report it can occasion-
ally be helpful to address the findings of the study with
respect to the clinical questions asked. However, this is
more commonly done in the report Summary/Impression.
Any interpretation or summary in the body of the report
should also be repeated in the report Summary/
Impression.
& Complementary information: Comparison with previous
examinations should be part of the FDG PET/CT report.
FDG PET/CT studies are more valuable if they are
interpreted in the context of other imaging examinations
(CT, PET/CT, MRI etc.) and clinical data.
& Assessment of response to therapy: If an FDG PET/CT
study is performed in the context of the assessment of
response to therapy, the extent and the intensity of the
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FDG uptake should be documented and compared to prior
measurements, if available. Examples of criteria for ther-
apy response with FDG as a metabolic biomarker have
been suggested by The European Organisation for Re-
search and Treatment of Cancer [68]. In 2009, Wahl
et al. suggested the so-called PERCIST criteria for
assessing solid tumour response [61]. Further, a five-
point scale has been proposed for assessment of lympho-
ma therapy response [80]. Reporting of the change in
intensity of the FDG uptake using semiquantitative pa-
rameters – expressed as absolute or relative change – can
be used for specific dedicated clinical questions. At pres-
ent, relative changes in SUV during therapy represent the
most robust parameters. The reliability of the results re-
ported will depend on having comparable patient prepa-
ration, injection and scanning protocols, as well as com-
parable data analysis.
Summary and diagnosis/impression
& Clearly identify the study as normal or abnormal.
& The question asked in the study requisition should be
directly addressed.
& If possible, a definite diagnosis should be stated. When-
ever possible this should provide a staging assessment
(TNM or other) stating whether there are categories of
uncertainty. Alternatively, a qualitative estimate of the
likelihood of a diagnosis and the differential diagnoses
should be given.
& If appropriate, repeat examinations and/or additional ex-
aminations should be recommended to clarify or confirm
findings.
& For therapy evaluation, serial studies should be compared,
using visual and/or semiquantitative assessment as
appropriate.
& Document the communication of urgent or emergency
findings to referring physicians or their deputy.
Additional notes
The Royal College of Radiologists provides recommenda-
tions on reporting that include relevant aspects that should
be taken into account [77]:
& Limitations of staging: Every diagnostic test has a thresh-
old. The threshold used may vary depending on the im-
plications for treatment (to optimise diagnostic accuracy
or according to treatment intent).
& Indeterminate lesions and management of uncertainty:
Indeterminate lesions should be the point of clinical–ra-
diological discussion and/or multidisciplinary review, if
better characterisation of the lesion will further affect
patient management. The options for resolving uncer-
tainties are discussion, further investigation, intervention
and active monitoring (watch and wait).
& Multidisciplinary team meetings: Multidisciplinary team
meetings allow a team approach to patient management to
take into account and evaluate all aspects of the disease
prior to individualised therapy planning. It should be
possible to review all relevant examinations in a multidis-
ciplinary meeting, especially when there is discrepancy
between clinical and imaging findings or other diagnostic
uncertainty. During the meetings, the results of the discus-
sions should be recorded, and discrepancies noted and, if
necessary, reported as an addendum to the imaging report.
If additional tests are needed, these should be scheduled as
soon as possible. The presence of a reporting radiologist or
nuclear medicine specialist is essential [72].
& Imaging the treated patient or follow-up studies: The
format of the report should mirror the one at base-
line. Reports of follow-up studies must include clear
statements regarding the detection of new disease as
this implies metabolic progression of disease. Also,
descriptions on the direction of change, indetermi-
nate lesions and mixed responses and findings at
variance with one another that may reflect different
pathologies should be stated [30].
For further reading see also the SNMMI’s reporting
guidance for oncological FDG PET/CT imaging [76],
the Royal College of Radiologists’ recommendations
on reporting [77] and the SNMMI’s Procedure Standard
for General Imaging.
Definitions of volumes of interest
Recommended tumour uptake metrics
& The maximum SUL or SUV (SULmax, SUVmax) is re-
quired for each lesion as specified in the study protocol
and/or as considered clinically relevant for routine clinical
studies. The SULmax and SUVmax are measures of the
single whole voxel in a particular lesion with highest/
maximum uptake. The maximum uptake should be de-
fined on original reconstructed PET images, i.e. no addi-
tional rebinning, resampling, smoothing or any other ma-
nipulation by the user is allowed.
& Use of a 3D peak VOI (providing SUVpeak and SULpeak)
may be determined (when possible) using a 3D 1.2 cm
diameter (and 1.0 mL volume) spherical VOI [61] posi-
tioned such that the average value across all positions
within the lesion is maximised. Often this coincides with
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the location (not value) of SUVmax and SULmax, but this
may not necessarily be the case in all situations.
& The TLG and MTV are of increasing interest and these
parameters or their change may have prognostic and/or
predictive value. These parameters should therefore be
reported, if available. These metrics requires a 3D delin-
eation or segmentation of the FDG-avid lesions. 3D VOIs
based on percentage of SUVmax or SULmax thresholds are
frequently used [48, 81] and most widely available. It is
recommended, when possible, to include the following 3D
region isocontour-based VOIs for reporting TLG and
MTV [48, 81, 82]:
– 3D isocontour at 41 % of the maximum pixel value (VOI41)
– 3D isocontour at 50 % of the maximum pixel value (VOI50)
& The MTV represents the volume of the above given VOI.
MTV41 is derived using VOI41 and MTV50 is derived
using VOI50. TLG is the product of the VOI average
SUVor SUL (SUVmean, SULmean) multiplied by the cor-
responding MTV. TLG41 is derived using VOI41 and
TLG50 using VOI50.
& In a longitudinal setting the quantitative metrics described
above should be derived using the sameVOI approach for all
FDG PET/CT examinations in the same patient. Changes in
SUL, TLG and MTV should be evaluated using the same
VOI approach for all PET/CT studies in the same patient.
Some considerations with respect to semiautomated
percentage threshold-based delineation methods
The isocontour described as VOI41 corresponds best with the
actual dimensions of the tumour, but only for higher tumour-
to-background values and nonheterogeneous tracer uptakes.
This VOI method, however, does not always result in useful
tumour definitions because of noise, tracer uptake inhomoge-
neities in tumour and background and sometimes low tumour-
to-background ratios. In that case, a VOI based on a higher
isocontour value (e.g. VOI50) should be chosen for all subse-
quent studies in the same patient when studies are performed
for tumour response assessment.
When VOIs are generated semiautomatically, it is not
always possible to generate a reliable VOI if there is a high
background or an area of high uptake (bladder, heart) close to/
adjacent to the lesion, or if there is low uptake in the lesion.
Therefore, semiautomatically generated VOIs must be
checked visually. Moreover, in the event of tracer uptake
heterogeneity, these VOIs may only delineate the most meta-
bolically active part of the tumour. If the VOIs are not reliable
and/or do not correspond visually with the lesion, only the
maximum SUV (normalised to body weight) and SUL and
possibly 3D SUVpeak and SULpeak should be used for
reporting.
Other tumour segmentation methods have been described
for MTVassessment and/or tumour delineation for radiother-
apy planning in the literature, such as contrast-oriented
methods [48, 83–85], gradient-based methods [86], iterative
methods [87] and fuzzy clustering/segmentation methods
[88]. These, however, are not routinely used and not widely
available for determining SUVs, although several methods do
outperform the simple percentage threshold-based methods
[83].
The authors realise the importance of using more accurate
and improved delineation methods than those recommended
above and, indeed, the use of more advanced methods is
encouraged [89]. In particular when FDG PET/CT-based tu-
mour delineations are used for radiotherapy planning, the
delineation methods used and the tumour segmentation ob-
tained should be critically reviewed and supervised. Specific
guidelines for the use of FDG PET/CT in radiotherapy have
been published elsewhere [14, 15, 90–92]. VOI methods other
than those recommended in these guidelines may be used
provided that at least the maximum uptake (SULmax), and
possibly the SULpeak, are always determined and reported as
well.
Liver uptake assessment
As suggested by Wahl et al. [61], assessment of liver SUL or
SUVmay be a useful quality index of an FDG PET/CT study.
Liver measurements may be assessed by placing a spherical
VOI of diameter 3 cm in the right upper lobe of the liver,
avoidingmalignancies and organ boundaries, as indicated also
in the QIBA FDG PET/CT profile [61]. Liver SULs or SUVs
should be reported along with lesion SUL or SUV data. The
study protocol or clinical guidelines should define acceptable
levels for liver SUL and required actions when specifications
are not met. For clinical studies that are quantitatively
assessed, mean liver SULs are expected to be within 1.0 and
2.2 (and mean liver SUVs within 1.3 and 3.0) [93]. Liver
SULs outside this range may indicate incorrect FDG admin-
istration or technical issues, and the use of quantitative anal-
ysis of the study should be reconsidered and the uncertainties
discussed in the study report.
Mediastinal uptake assessment
Measurement of the mediastinal blood pool can be very useful
for assessing what is considered normal or physiological FDG
uptake. In recent years, it has been used for the interim
evaluation of response to therapy in lymphoma. It is calculated
by drawing several VOIs inside the thoracic aorta and mea-
suring the (mean) uptake inside the vessel, taking care not to
include in the VOI the vessel wall, where uptake can be
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slightly higher when there is vascular inflammation. Blood
pool SUL measurements are expected to be around 1.2 (and
blood pool SUVs around 1.6) [61, 93, 94].
Quality control and interinstitution PET/CT system
performance harmonisation
PET/CT system quality control
The impacts of various technical, physics-related and biolog-
ical factors have been described extensively [58]. The use of
SUVs in multicentre oncology FDG PET/CT studies requires
a standardised interinstitution calibration procedure in order to
facilitate the exchangeability of SUVs between institutions. It
is also important that all participating institutions employ
similar methodologies. In order to ensure the comparability
of SUVs, a minimum set of QC procedures must be per-
formed, including:
& Daily QC (both the PET and the CT component of the
PET/CT system)
& Calibration QC and cross-calibration of PET/CT system
with the institution’s own dose calibrator or against a dose
calibrator (e.g. that of an FDG provider) which is gener-
ally used to determine patient-specific FDG activities
& Image quality and recovery coefficients (IQRC)
Note that these QC measures do not replace any QC
measures required by national law or legislation or those
recommended by local nuclear medicine societies. A brief
summary of PET and PET/CT QC procedures, specifically
recommended here to ensure accurate SUV quantification, is
given below.
Daily QC
The aim of daily QC is to determine whether the PET/
CT system is functioning well, and specifically to check
for detector failure and/or electronic drift. Most commer-
cial systems are equipped with an automatic or semiau-
tomatic procedure for performing daily QC. For some
systems, the daily QC includes tuning of hardware and/
or settings (such as gains). Thus both the procedure and
its name differ among systems. In all cases all daily QC
measures and/or daily set-up/tuning measurements should
be performed according to the manufacturer’s specifica-
tions. Users should check whether the daily QC meets
the specifications. When available, a daily PET/CT study
of a cylindrical phantom filled with a 68Ge or another
long-lived positron-emitting isotope may be acquired
[95]. This test enables assessment and reduction of
longitudinal variability due to calibration error and/or
PET/CT system sensitivity drifts. Inspection of uniformi-
ty and quantitative accuracy of the reconstructed PET
image may help identify technical failures that were not
detected using the routine daily QC procedures. In addi-
tion, when possible, sinogram data should be inspected
to check for detector failure.
Calibration QC and cross-calibration of PET/CT systems
The aim of cross-calibration is to determine the correct
and direct (cross- or relative) calibration of the PET/CT
system with the institution’s own dose calibrator or
against another one which is used to determine
patient-specific FDG activities [96]. If FDG activity is
ordered directly from and supplied by an external sup-
plier, cross-calibration of the PET/CT system should be
carried out using a calibration sample supplied by that
provider. At the time of writing this version of the
guidelines, standard calibration sources for both dose
calibrators and PET/CT systems are not yet widely
available, although some initiatives are being undertaken
[97]. Therefore, at present these guidelines recommend
a proper cross-calibration between the dose calibrator
used for patient administered activity and the PET/CT
system as a minimal standard. Calibration QC proce-
dure, SOP and specifications are provided in the UPICT
oncology FDG PET/CT protocol [30] and by EARL
[46].
Image quality and recovery coefficient harmonisation
Although correct cross-calibration is guaranteed using the QC
procedure described above, differences in SUV quanti-
fication may still occur between centres as a result of
differences in the reconstruction and data analysis meth-
odology [60, 98]. To this end an IQRC QC procedure
has been developed:
& To determine/check the correctness of a calibration and
quantification using a noncylindrical (calibration) phan-
tom containing a set of high-contrast spherical objects.
& To measure standardised ‘activity concentration or SUV
recovery coefficients’ as a function of sphere (tumour)
size.
The main aim of the IQRC QC procedure is to guarantee
comparable quantitative PET/CT system performance with
respect to SUV recovery and quantification. Details on the
IQRC QC procedure, SOP and standardised specifications are
provided by EARL [46].
348 Eur J Nucl Med Mol Imaging (2015) 42:328–354
Minimum frequency of PET/CT system QC procedures
Procedure Frequency
Daily QC (outlined above) Daily
Cross-calibration Quarterly and always immediately
following software and hardware
revisions/upgrades and immediately
following new set-ups/normalisations
IQRC Annually and always following
reconstruction/system software
adjustments, especially adjustments
to the reconstruction and/or data
analysis (region of interest) software/
hardware, and following relevant system
hardware changes
CT quality control (CT-QC)
Several documents and reports on CT quality control (CT-QC)
have been published and are listed below for readers’ infor-
mation. An overview of CT-QC is given in, for example, the
“Equipment Specifications” and “Quality Control” sec-
tions of the American College of Radiology Practice
Guideline for the Performance of Computed Tomogra-
phy of the Extracranial Head and Neck in Adults and
Children, the American College of Radiology Practice
Guideline for the Performance of Pediatric and Adult
Thoracic Computed Tomography (CT), and the Ameri-
can College of Radiology Practice Guideline for the
Performance of Computed Tomography (CT) of the
Abdomen and Computed Tomography (CT) of the Pel-
vis and in IPEM report 91. In addition, CT performance
monitoring guidelines are given in the American Col-
lege of Radiology Technical Standard for Medical Phys-
ics Performance Monitoring of Computed Tomography
(CT) Equipment.
Additional QC measures
& Alignment of PET and CT images on a PET/CT
system should be checked according to the proce-
du r e and f r equency r ecommended by the
manufacturer.
& Set-up and normalisation for both PET and CT sys-
tems should be performed according to the proce-
du r e and f r equency r ecommended by the
manufacturer.
& All devices involved (PET/CT systems, dose calibra-
tors, well counters, clocks, scales) should be main-
tained according to the manufacturers’ recommenda-
tions or following national guidelines [99]. This
includes preventive and corrective maintenance re-
quired to ensure correct and accurate functioning of
the devices.
& Calibration should always be performed or correct
(cross-)calibration should be verified (by means of QC)
after maintenance and software upgrades.
& The accuracy of scales used to measure height and
to weigh patients should be checked at installation
and after maintenance and/or according to the
procedure and frequency recommended by the
manufacturer.
Radiation exposure to the patient
& The radiation dose with FDG PET/CT is the combination
of the radiation exposure from the radiopharmaceutical
(Table 1) and the CT study. The radiation dose of diag-
nostic CT is a matter of concern, particularly for paediatric
examinations. The mean dose for a CT scan depends on
applications, protocols and CT systems. Especially in
children but also in adults it is important to optimise the
radiation exposure with respect to the diagnostic question.
Recent advances in technology have allowed the radiation
Table 1 Radiation dosimetry for
FDG Adult 15 years 10 years 5 years 1 year
Recommended administered activity at
nominal weight (MBq) [51]
See section VII 302 189 120 70
Nominal weight (kg) – 55 32 19 10
Organ receiving highest dose [25] Bladder Bladder Bladder Bladder Bladder
Absorbed dose per unit activity
at voiding interval (mGy/MBq) [25]
1.3×10−1 1.6×10−1 2.5×10−1 3.4×10−1 4.7×10−1
Voiding interval (h) [25] 3.5 3.5 3.5 3.0 2.0
Effective dose (mSv/MBq) [25] 1.9×10−2 2.4×10−2 3.7×10−2 5.6×10−2 9.5×10−2
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doses to be significantly reduced relative to a conventional
CT or PET examination.
& The coefficient for effective dose from FDG in adults is
1.9×10−2 mSv/MBq according to ICRP publication 106
[25], i.e. about 3.5 mSv for an administered activity of
185 MBq. The radiation exposure related to a CT scan
carried out as part of an FDG PET/CT study depends on
the intended use of the CT study and may differ from
patient to patient: the CT scan can be a very low-dose
scan (with lower tube voltage and current) for attenuation
correction only, or as a low-dose or intermediate-dose scan
for attenuation correction and localisation of PET lesions,
or additionally a diagnostic CT scan can be indicated (in
most cases with intravenous contrast agent administration
and deep inspiration for chest CT) for a full diagnostic CT
examination. The effective CT dose ranges from 1 to
20 mSv and may be even higher for a static high-
resolution diagnostic CT examination. Given the variety
of CT systems and protocols, the radiation exposure for a
FDG PET/CT study should be estimated specifically for a
given imaging system and protocol. Guidelines provided
by European radiological societies should be consulted
regarding effective dose from the CT examination.1
& The choice of imaging protocol strongly depends on the
clinical question and must be considered for every single
case. Paediatric studies require special attention. For the
optimisation of FDG PET/CT studies, dose reduction
techniques should be considered.
Additional considerations
At the time of writing this new version of the FDG PET/CT
guidelines for tumour imaging, several international collabo-
rative activities are being undertaken to optimise the use of
FDG PET/CTas a quantitative imaging biomarker. During the
drafting of the guidelines we took the following (draft) docu-
ments into consideration: (1) the QIBA FDG PET/CT profile
[56] and (2) the UPICToncology FDG PET/CT protocol [30].
In both documents presently being drafted and revised, clear
definitions and general recommendations for both system
performance and image procedures are provided. The
EANM guidelines presented here use these general recom-
mendations and attempt to translate them into standardised
imaging procedure standards applicable to the earlier
published European FDG PET/CT guidelines. It should be
noted that both the previous EANM guidelines and this new
version specifically aim to obtain harmonised SUV data in a
multicentre setting. Moreover, the present new version pro-
vides an update of the earlier version and attempts to address
some new insights and technological developments.
History of the document
These guidelines are a joint project of the EANM Oncology
Committee, the EANM Physics Committee and the SNMMI
Committee onGuidelines. These guidelines provide an update
of the previously published FDG PET and PET/CT: EANM
Procedure Guidelines for Tumour PET Imaging: version 1.0,
and the SNMMI Procedure Guidelines for Tumour Imaging
with 18F-FDG PET/CT 1.0, and address new technologies and
developments. There have been major changes in some sec-
tions, but others may have hardly been changed. Indeed, there
is similarity with the previous version and certain sections
have not been altered. Moreover, consideration is given to
compliance with international initiatives, such as those by the
Quantitative Imaging Biomarkers Alliance (QIBA) [30, 56].
In addition, the previous and this version of the guidelines are
based on the following three documents:
The procedure guidelines for tumour imaging with FDG
PET/CT of the SNMMI: “Procedure guideline for tumour
imaging with 18F-FDG PET/CT 1.0.” [21].
The German guidelines for FDG-PET/CT in oncology of
the Deutsche Gesellschaft für Nuklearmedizin: “FDG-PET/
CT in der Onkologie” [99].
The Netherlands protocol for standardisation of quantita-
tive whole-body FDG PET/CT: “Applications of F18-FDG-
PET in Oncology and Standardisation for Multi-Centre Stud-
ies” [49].
An overview of other and previously published guidelines
[10, 21, 61, 68, 78, 99–106] or recommendations can be found
in the supplement issue of the Journal of Nuclear Medicine
2009 [58].
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